BridgeMD
New treatment option for Multiple Myeloma
Official title Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
ClinicalTrials.gov ID: NCT06429150
What this study is testing
What is CAR-T cells?
CAR-T cells is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for multiple myeloma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Male and female people with multiple myeloma or plasmacytoma
- Strictly complete remission (sCR) is a treatment goal
- Expected survival \> 12 weeks
- After prior auto-SCT is eligible regardless of other prior therapies
- Adequate venous access for apheresis, and no other contraindications for leukapheresis
You likely can't join if
- Pregnant or lactating women
- Uncontrolled active infection
- Active HIV, hepatitis B or hepatitis C infection
- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
- Any medical conditions that may preclude participation
See the full eligibility criteria
- Male and female people with multiple myeloma or plasmacytoma
- Strictly complete remission (sCR) is a treatment goal
- Expected survival \> 12 weeks
- After prior auto-SCT is eligible regardless of other prior therapies
- Adequate venous access for apheresis, and no other contraindications for leukapheresis
- Voluntary informed consent is given and commitment to continued follow-up
- Pregnant or lactating women
- Uncontrolled active infection
- Active HIV, hepatitis B or hepatitis C infection
- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
- Any medical conditions that may preclude participation
The study team makes the final eligibility decision.
Where it's taking place
- Shenzhen, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shenzhen, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.